Meeting Report
2021–2022 Drug Updates in Solid Tumors
Presented by Kirollos Hanna, PharmD, BCPS, BCOP
From M Health Fairview and Mayo Clinic College of Medicine, Maple Grove, Minnesota
Presenter’s disclosure of conflict of interest is found at the end of this article.
J Adv Pract Oncol 2023;14(3):227–231 |
https://doi.org/10.6004/jadpro.2023.14.3.9 |
© 2023 Harborside™
ABSTRACT
During JADPRO Live 2022, Kirollos Hanna, PharmD, BCPS, BCOP, briefed advanced practitioners on key FDA approvals from late 2021 to late 2022. He described mechanisms of action that are unique across some malignancies, as well as mechanisms of action that clinicians can utilize through an expanded indication or across other solid malignancies. Finally, he discussed safety profiles and what advanced practitioners can and should do in monitoring across solid tumors.
For access to the full length article, please
sign in.
